PCOS renamed to PMOS after global collaboration for better awareness and care
Consensus Summary
Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) after a 14-year global effort led by Prof Helena Teede and supported by 56 medical societies and patient groups. The change, announced on May 12, 2026, at the European Congress of Endocrinology in Prague and published in *The Lancet*, aims to address the misleading 'polycystic' term, which focused disproportionately on ovarian cysts and reproductive issues. Research confirms women with PMOS do not have a higher rate of abnormal cysts, and the new name emphasizes its broader impact on metabolism, diabetes, cardiovascular health, and mental well-being. The renaming process involved over 22,000 survey responses and input from patients like Lorna Berry, who advocated for a name reflecting the hormonal and systemic nature of the condition. Both sources highlight that the new name will be integrated into 2028 international guidelines, with hopes of reducing misdiagnoses and improving care for the 170 million women affected worldwide. Patient stories underscore long-standing frustrations with delayed diagnoses, weight stigma, and a lack of holistic treatment, with advocates like Maddy Mavrikis and Hannah Bambra expressing hope the change will lead to better awareness and medical responses.
â Verified by 2+ sources
Key details reported by multiple sources:
- Polycystic ovary syndrome (PCOS) has been renamed to polyendocrine metabolic ovarian syndrome (PMOS) after 14 years of collaboration between international societies and patient groups across six continents.
- The renaming was announced at the European Congress of Endocrinology in Prague on May 12, 2026, and published in *The Lancet*.
- The name change was spearheaded by Prof Helena Teede, director of Melbourneâs Monash Centre for Health Research & Implementation.
- PMOS affects approximately 170 million women worldwide, or one in eight women.
- The new name reflects the conditionâs broader impact on metabolism, diabetes risk, cardiovascular health, and mental health, not just reproductive issues.
- The renaming process involved 56 medical and patient societies globally, with input from over 300 readers living with PCOS in the Guardianâs survey.
- The new name will be fully implemented in the next update to international guidelines for managing the condition, scheduled for 2028.
- Research shows women with PMOS do not have a higher rate of abnormal ovarian cysts than women without the condition, challenging the 'polycystic' misnomer.
- Lorna Berry, a patient advocate, was involved in the renaming process and described the condition as primarily hormonal, not just reproductive.
Points of Difference
Details reported by only one source:
- Maddy Mavrikis, diagnosed at 15, was told she would 'probably never have children' and later learned this was incorrect; her ultrasound showed no 'polycystic' ovaries despite the diagnosis.
- Mavrikisâ mother, who works in pathology, questioned the GP about the name, suggesting it was more of a hormonal condition.
- Mavrikis experienced weight stigma from doctors, who advised her not to gain weight without addressing lifestyle interventions like diet and exercise.
- Rosemary (name changed) was told by her GP at 17 that a PCOS diagnosis wouldnât be useful unless she wanted children, and she faced reductive stereotypes about appearance ('prominent eyebrow ridges and a large belly').
- The Guardian received over 300 reader stories about struggles with diagnosis and care, with many describing patchy or dismissive treatment.
- Academic discussions about renaming PCOS began as early as 1995, with a 2012 US National Institutes of Health forum recommending a change.
- Terhi Piltonen, lead author of the cyst study and professor at Finlandâs University of Oulu, emphasized the goal of improving patient care with the name change.
- Hannah Bambra, 34, lives with PMOS and hopes the name change shifts medical thinking to consider hormonal imbalances beyond fertility.
- Magdalena Simonis, a GP and womenâs health expert from the University of Melbourne, submitted a survey response on behalf of the Royal Australian College of General Practitioners.
- Dr. Simonis noted many women are diagnosed when seeking help for weight gain, a common early symptom of PMOS.
- The ABC highlights that PMOS can present differently at various life stages: acne in younger women, fertility issues in mid-life, and metabolic features like insulin resistance in older women.
Contradictions
Conflicting information between sources:
- The Guardian mentions a 'transition period' before full implementation of the new name, while the ABC does not specify this detail.
Source Articles
âUnprecedentedâ global effort gives new name to polycystic ovary syndrome â and new hope to millions of women
Decades-long campaign powered by patient perspectives results in switch from PCOS â a name that caused confusion and undue suffering â to PMOS ⢠What is PCOS, what are the symptoms and treatment, and why is it being renamed PMOS? ⢠âI still want to screamâ: the loneliness and confusion of living with PMOS After more than a decade of global consultation, polycystic ovary syndrome (PCOS) â a condition that affects one in eight women â has been renamed. The hormonal disorder, estimated to impact 17
The name of this health condition was 'very inaccurate'. Now it's changed
Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS), a move health experts say will lead to faster diagnoses and better treatment for women of all ages.